Fate Therapeutics Inc (FATE)

[jondoeuk]

ASH abstracts:

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma https://ash.confex.com/ash/2020/webprogram/Paper142750.html

Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment https://ash.confex.com/ash/2020/webprogram/Paper141506.html

Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy https://ash.confex.com/ash/2020/webprogram/Paper141095.html

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper138527.html

Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse https://ash.confex.com/ash/2020/webprogram/Paper138930.html

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML https://ash.confex.com/ash/2020/webprogram/Paper137138.html

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC https://ash.confex.com/ash/2020/webprogram/Paper139760.html

cGMP Mass Production of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line https://ash.confex.com/ash/2020/webprogram/Paper141922.html

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper141606.html

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies https://ash.confex.com/ash/2020/webprogram/Paper142423.html

Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor https://ash.confex.com/ash/2020/webprogram/Paper141507.html

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2020/webprogram/Paper137715.html